PE20220590A1 - Agonistas del receptor del peptido-1 similar al glucagon - Google Patents

Agonistas del receptor del peptido-1 similar al glucagon

Info

Publication number
PE20220590A1
PE20220590A1 PE2021002176A PE2021002176A PE20220590A1 PE 20220590 A1 PE20220590 A1 PE 20220590A1 PE 2021002176 A PE2021002176 A PE 2021002176A PE 2021002176 A PE2021002176 A PE 2021002176A PE 20220590 A1 PE20220590 A1 PE 20220590A1
Authority
PE
Peru
Prior art keywords
glucagon
peptide
receptor agonists
compound
preparing
Prior art date
Application number
PE2021002176A
Other languages
English (en)
Inventor
David Andrew Coates
Todd Fields
Joseph Daniel Ho
Fucheng Qu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20220590A1 publication Critical patent/PE20220590A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referido a compuesto seleccionado entre I, II, II y IV. Estos compuestos son agonistas del receptor del peptido-1 similar al glucagon. Tambien se refiere a metodos de preparacion de dicho compuesto, una composicion farmaceutica que comprende dicho compuesto, y su uso en el tratamiento de la diabetes mellitus tipo II.
PE2021002176A 2019-06-28 2020-06-19 Agonistas del receptor del peptido-1 similar al glucagon PE20220590A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868117P 2019-06-28 2019-06-28
US201962904906P 2019-09-24 2019-09-24
PCT/US2020/038617 WO2020263695A1 (en) 2019-06-28 2020-06-19 Glucagon-like peptide 1 receptor agonists

Publications (1)

Publication Number Publication Date
PE20220590A1 true PE20220590A1 (es) 2022-04-22

Family

ID=71575804

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002176A PE20220590A1 (es) 2019-06-28 2020-06-19 Agonistas del receptor del peptido-1 similar al glucagon

Country Status (31)

Country Link
US (2) US11655242B2 (es)
EP (2) EP4302826A3 (es)
JP (1) JP7256300B2 (es)
KR (1) KR20220012924A (es)
CN (1) CN114008033A (es)
AU (1) AU2020309064B2 (es)
CA (1) CA3144055C (es)
CL (1) CL2021003419A1 (es)
CO (1) CO2021017433A2 (es)
CR (1) CR20210599A (es)
DK (1) DK3989972T3 (es)
DO (1) DOP2021000273A (es)
EC (1) ECSP21093576A (es)
ES (1) ES2970173T3 (es)
FI (1) FI3989972T3 (es)
HR (1) HRP20231586T1 (es)
HU (1) HUE065080T2 (es)
IL (1) IL288479A (es)
JO (1) JOP20210337A1 (es)
LT (1) LT3989972T (es)
MD (1) MD3989972T2 (es)
MX (1) MX2021015328A (es)
PE (1) PE20220590A1 (es)
PL (1) PL3989972T3 (es)
PT (1) PT3989972T (es)
RS (1) RS64940B1 (es)
SA (1) SA521431209B1 (es)
SI (1) SI3989972T1 (es)
TW (1) TWI751585B (es)
WO (1) WO2020263695A1 (es)
ZA (1) ZA202109587B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
BR112022007627A2 (pt) 2019-10-25 2022-07-12 Gilead Sciences Inc Compostos moduladores do glp-1r
CN114761395A (zh) * 2019-12-02 2022-07-15 现代药品株式会社 Glp-1受体激动剂
KR20220156535A (ko) 2020-02-07 2022-11-25 가셔브룸 바이오, 인크. 헤테로사이클릭 glp-1 작용제
US20230165846A1 (en) * 2020-02-13 2023-06-01 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR102563111B1 (ko) * 2020-03-18 2023-08-04 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
TWI825398B (zh) * 2020-03-18 2023-12-11 南韓商Ｌｇ化學股份有限公司 Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法
CN116323599A (zh) 2020-08-06 2023-06-23 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4204415A1 (en) 2020-08-28 2023-07-05 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
CA3200245A1 (en) * 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
US20240300928A1 (en) * 2021-04-08 2024-09-12 Lg Chem, Ltd. Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
US11858918B2 (en) 2021-04-21 2024-01-02 Gilead Sciences, Inc. GLP-1R modulating compounds
MX2023012918A (es) * 2021-05-03 2024-03-13 Carmot Therapeutics Inc Agonistas del receptor del péptido 1 similar al glucagón (glp-1) de bencimidazoilo, composiciones farmacéuticas que los comprenden y métodos para su uso.
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2023038039A1 (ja) 2021-09-08 2023-03-16 塩野義製薬株式会社 抗肥満作用の関与する疾患の予防及び治療用医薬
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
KR20240073108A (ko) 2021-10-05 2024-05-24 아스트라제네카 아베 Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
AU2023232184A1 (en) 2022-03-08 2024-09-26 Guangzhou Apichope Pharmaceutical Co., Ltd. Benzo bicyclic compound, and preparation method and application thereof
WO2024041609A1 (zh) * 2022-08-24 2024-02-29 广州市联瑞制药有限公司 苯并双环类化合物及其制备方法和应用
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120053180A1 (en) * 2010-08-27 2012-03-01 Chemizon, A Division Of Optomagic Co., Ltd. Cyclohexane analogues as gpr119 agonists
TWI537262B (zh) * 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
WO2018098781A1 (en) * 2016-12-01 2018-06-07 Eli Lilly And Company Pyrrolidinone compounds
PL3555064T3 (pl) * 2016-12-16 2023-03-06 Pfizer Inc. Agoności receptora GLP-1 i ich zastosowania
TWI707683B (zh) * 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
WO2019239371A1 (en) 2018-06-15 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
KR20210106447A (ko) * 2018-11-22 2021-08-30 치루 레고르 테라퓨틱스 인코포레이티드 Glp-1r 효능제 및 그의 용도
KR20210152513A (ko) * 2019-04-12 2021-12-15 치루 레고르 테라퓨틱스 인코포레이티드 Glp-1r 작용제 및 이의 용도
US10954221B2 (en) * 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
BR112022007627A2 (pt) * 2019-10-25 2022-07-12 Gilead Sciences Inc Compostos moduladores do glp-1r
BR112022009287A2 (pt) 2019-11-15 2022-08-09 Ildong Pharmaceutical Co Ltd Agonista do receptor de glp-1 e uso do mesmo
CN114761395A (zh) 2019-12-02 2022-07-15 现代药品株式会社 Glp-1受体激动剂
EP4097097A1 (en) 2020-01-29 2022-12-07 Gilead Sciences, Inc. Glp-1r modulating compounds
US20230165846A1 (en) 2020-02-13 2023-06-01 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TWI825398B (zh) * 2020-03-18 2023-12-11 南韓商Ｌｇ化學股份有限公司 Glp-1 受體促效劑、包含該促效劑之醫藥組成物及其製備方法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
US20230295154A1 (en) 2020-04-29 2023-09-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Also Published As

Publication number Publication date
AU2020309064B2 (en) 2023-08-17
FI3989972T3 (fi) 2024-01-24
CR20210599A (es) 2021-12-22
HRP20231586T1 (hr) 2024-03-15
MX2021015328A (es) 2022-01-18
ES2970173T3 (es) 2024-05-27
ZA202109587B (en) 2024-07-31
DK3989972T3 (da) 2023-12-04
DOP2021000273A (es) 2022-03-15
JOP20210337A1 (ar) 2023-01-30
CA3144055A1 (en) 2020-12-30
CA3144055C (en) 2024-01-02
CO2021017433A2 (es) 2022-04-19
ECSP21093576A (es) 2022-01-31
US11655242B2 (en) 2023-05-23
EP4302826A3 (en) 2024-04-17
BR112021023923A2 (pt) 2022-01-25
SI3989972T1 (sl) 2024-01-31
PT3989972T (pt) 2023-12-04
WO2020263695A1 (en) 2020-12-30
US20230250092A1 (en) 2023-08-10
HUE065080T2 (hu) 2024-04-28
TW202115040A (zh) 2021-04-16
EP4302826A2 (en) 2024-01-10
AU2020309064A1 (en) 2022-01-27
EP3989972A1 (en) 2022-05-04
KR20220012924A (ko) 2022-02-04
US20200407347A1 (en) 2020-12-31
IL288479A (en) 2022-01-01
CL2021003419A1 (es) 2022-09-23
MD3989972T2 (ro) 2024-05-31
RS64940B1 (sr) 2024-01-31
TWI751585B (zh) 2022-01-01
CN114008033A (zh) 2022-02-01
PL3989972T3 (pl) 2024-03-25
JP7256300B2 (ja) 2023-04-11
EP3989972B1 (en) 2023-11-08
JP2022540044A (ja) 2022-09-14
LT3989972T (lt) 2023-12-27
SA521431209B1 (ar) 2024-08-05

Similar Documents

Publication Publication Date Title
PE20220590A1 (es) Agonistas del receptor del peptido-1 similar al glucagon
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
ECSP21004913A (es) Compuestos coagonistas de gip/glp1
PE20210162A1 (es) Analogos de incretina y sus usos
ZA202007304B (en) Glp-1 receptor agonists and uses thereof
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
CL2019001465A1 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.
NZ740644A (en) Glucagon receptor agonists
GT201500049A (es) Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico
PE20150900A1 (es) Derivados de exendida-4 como agonistas duales de glp1/glucagon
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
AR099977A1 (es) Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
CL2012002635A1 (es) Péptido que presenta actividad para el receptor del péptido insulinotrópico dependiente de glucosa (gip-r) y para el receptor del péptido-1 similar al glucagón (glp-1-r) y son selectivos sobre el receptor del glucagón (gluc-r); formulación farmacéutica que lo comprende; y su uso para el tratamiento de diabetes mellitus y para la pérdida de peso.
ES2687651T3 (es) Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
DOP2006000219A (es) Indoles de acilo, composiciones que contienen dichos compuestos y procedimientos de uso
EA201170302A1 (ru) Процессированные аналоги глюкозозависимого инсулинотропного полипетида
AR105284A1 (es) Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CL2020002574A1 (es) Análogos novedosos de glp-1
CL2011002182A1 (es) Compuestos heterociclicos que contienen 2 o mas heterociclos con n como heteroatomos del ciclo, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso en el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras enfermedades..
CL2022001724A1 (es) Método y aplicación de preparación de compuesto como agente de degradación de proteínas
CL2017002913A1 (es) Tratamiento de la hipoglucemia posbariátrica con exendina (9-39)
PE20150607A1 (es) Composicion farmaceutica que comprende fimasartan e hidroclorotiazida
ECSP23095307A (es) Agonista del receptor de glp-1 y composición y uso del mismo
EA202192296A1 (ru) Терапевтическое применение дулаглутида